Navigation Links
Codexis Names Lori Giver VP Systems Biology
Date:3/31/2009

REDWOOD CITY, Calif., March 31 /PRNewswire/ -- Codexis, Inc. today announced Lori Giver, Ph.D., has been named to the new position of Vice President, Systems Biology for Codexis Bioindustrials. She is responsible for cellular engineering, molecular biology, and computational biology. Dr. Giver reports to David Anton, Ph.D., Vice President, Bioindustrials Research and Development.

Dr. Giver is a widely-respected researcher in the directed evolution of genes and proteins. She joined Codexis in 2002 from Maxygen, where she was responsible for biocatalyst discovery and development. At Codexis, she has held a series of scientific leadership roles ranging from Associate Director, Research & Development to her most recent position as Senior Director, Evolution Technology.

She received a bachelor's degree in molecular and cell biology from the University of California at Berkeley, and a Ph.D. in molecular, cell and developmental biology from Indiana University, Bloomington, where she focused on the directed evolution of nucleic acids with Dr. Andrew Ellington. Dr. Giver did post-doctoral research in directed evolution of proteins at the California Institute of Technology with advisor Dr. Frances Arnold, a pioneer in the field of directed evolution and biocatalysis.

"Lori Giver's contribution to the development of today's strong and broad Codexis technology platform has been invaluable," Dr. Anton said. "She is one of the original core team of scientists that built both our expertise in biocatalysis and our world-class reputation in this field. Her appointment recognizes the role that systems biology, in combination with biocatalysis, will play in finding solutions to the critical need for renewable fuels and future clean technology products. Lori's advancement to our senior scientific leadership team recognizes her strong personal and professional dedication to our company, to her colleagues, and to finding technology solutions to the major challenges facing our society."

Codexis, Inc. is a clean technology company. The company develops industrial biocatalysts, including enzymes and microbes. Codexis technology is used in the energy industry to enable next generation, non-food biofuels and by global pharmaceutical companies for cost-effective manufacturing of human therapeutics. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit www.codexis.com.

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis, Teva in Licensing Agreement Final
2. Codexis Names Vice President, Intellectual Property
3. Codexis, Arch Announce Expanded Collaboration
4. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Codexis Names David Anton VP Bioindustrials R&D
6. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
7. Rothwell, Wolf Elected to Codexis Board
8. Codexis Opens Singapore Laboratory
9. Bruce Pasternack Elected to Codexis Board
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
Breaking Biology Technology:
(Date:3/23/2017)... 2017 The report "Gesture Recognition and Touchless Sensing Market ... - Global Forecast to 2022", published by MarketsandMarkets, the market is expected to ... between 2017 and 2022. Continue Reading ... ... ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
Breaking Biology News(10 mins):